The question appears to be a search for information about neutropenia in relation to the drug Kisqali.
What is Neutropenia with Kisqali?
Neutropenia is a condition characterized by an abnormally low level of neutrophils, a type of white blood cell crucial for fighting infection. Kisqali (ribociclib), used to treat certain types of breast cancer, can cause neutropenia as a side effect [1]. This reduction in neutrophils can increase the risk of infections [2].
How Common is Neutropenia with Kisqali?
Neutropenia is a frequent side effect of Kisqali treatment. In clinical trials, a significant percentage of patients experienced neutropenia, with Grade 3 or 4 neutropenia (severe) occurring in a substantial number of participants [1].
What are the Treatment Guidelines for Kisqali-Induced Neutropenia?
Treatment for neutropenia associated with Kisqali typically involves dose adjustments. This may include interrupting the Kisqali dose, reducing the dose, or permanently discontinuing the drug, depending on the severity of the neutropenia [1]. Monitoring blood cell counts regularly is essential during treatment [2].
Why is Neutropenia a Concern with Cancer Drugs?
Neutropenia is a significant concern with many chemotherapy and targeted cancer therapies because it compromises the body's immune system. This makes patients more susceptible to bacterial, viral, and fungal infections, which can become severe or life-threatening. Managing neutropenia is a critical aspect of patient care during cancer treatment to maintain treatment efficacy and patient safety [2].
When Does Neutropenia Typically Occur with Kisqali?
Neutropenia often occurs early in the course of Kisqali treatment, typically within the first few cycles. However, it can develop at any time during therapy [1]. Close monitoring of blood counts is therefore important throughout the treatment duration.
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209773s027lbl.pdf
2. https://www.drugpatentwatch.com/blogs/neutropenia-and-cancer-treatment